Evidence map›Paper›PMID 38570429›Full record

ArticleMolecular neurobiology2024

Post-COVID-19 Hyposmia Does Not Exhibit Main Neurodegeneration Markers in the Olfactory Pathway.

Tommaso Schirinzi, Daniela Maftei, Riccardo Maurizi, Maria Albanese, Clara Simonetta, Roberta Bovenzi, Jacopo Bissacco, Davide Mascioli, Laura Boffa, Maria Grazia Di Certo and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Tommaso SchirinziUnit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy. t.schirinzi@yahoo.com.
Daniela MafteiDepartment of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy.
Riccardo MauriziUnit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Rome, Italy.
Maria AlbaneseUnit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.
Clara SimonettaUnit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.
Roberta BovenziUnit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.
Jacopo BissaccoUnit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.
Davide MascioliUnit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.
Laura BoffaUnit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.
Maria Grazia Di CertoDepartment of Biochemistry and Cell Biology, National Research Council of Italy, Rome, Italy.
Francesca GabanellaDepartment of Biochemistry and Cell Biology, National Research Council of Italy, Rome, Italy.
Beatrice FrancavillaUnit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Rome, Italy.
Stefano Di GirolamoUnit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Rome, Italy.
Nicola Biagio MercuriUnit of Neurology, Department of Systems Medicine, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy.
Francesco Maria PassaliUnit of ENT, Department of Clinical Sciences and Translational Medicine, Tor Vergata University of Rome, Rome, Italy.
Roberta LattanziDepartment of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy.
Cinzia SeveriniDepartment of Biochemistry and Cell Biology, National Research Council of Italy, Rome, Italy.
University of Rome Tor Vergata · ITNational Research Council · ITSapienza University of Rome · IT

Funding

Ministero dell'Università e della Ricerca DSB.AD006.371 "INVECCHIAMENTO ATTIVO E IN SALUTE (FOE 2022)Sapienza Università di Roma SEED PNR (2021) "PROKINETICIN 2: a new potenzial neuroinflammatory biomarker in Alzheimer disease"
6 · The paper itself

Abstract

The biological substrate of persistent post-COVID-19 hyposmia is still unclear. However, as many neurodegenerative diseases present with smell impairment at onset, it may theoretically reflect degeneration within the central olfactory circuits. However, no data still exist regarding the post-COVID-19 patients. As the olfactory neurons (ONs) mirror pathological changes in the brain, allowing for tracking the underlying molecular events, here, we performed a broad analysis of ONs from patients with persistent post-COVID-19 OD to identify traces of potential neurodegeneration. ONs were collected through the non-invasive brushing of the olfactory mucosa from ten patients with persistent post-COVID-19 hyposmia (lasting > 6 months after infection) and ten age/sex-matched controls. Immunofluorescence staining for protein quantification and RT-PCR for gene expression levels were combined to measure ONs markers of α-synuclein, amyloid-β, and tau pathology, axonal injury, and mitochondrial network. Patients and controls had similar ONs levels of oligomeric α-synuclein, amyloid-β peptide, tau protein, neurofilament light chain (NfL), cytochrome C oxidase subunit 3 (COX3), and the heat shock protein 60 (HSP60). Our findings thus did not provide evidence for synucleinopathy and amyloid-β mismetabolism or gross traces of neuronal injury and mitochondrial dysfunction within the olfactory system in the early phase of persistent post-COVID-19 hyposmia.

Indexed as

Amyloid beta-PeptidesAnosmiaBiomarkersCOVID-19Olfactory Pathwaystau ProteinsAdultAgedalpha-SynucleinFemaleHumansMaleMiddle AgedNeurodegenerative DiseasesNeurofilament ProteinsOlfaction Disordersalpha-SynucleinAmyloid beta-PeptidesBiomarkersNeurofilament Proteinstau ProteinsHyposmiaLong-COVIDNeurodegenerationOlfactory dysfunctionOlfactory neuronsPost-COVID

Identifiers

PMID38570429
PMCPMC11496343
OpenAlexW4393946110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.